Pharmascience Canada markets generic Prpms-PAZOPANIB tablets

After Pharmascience International, it is now Pharmascience Canada’s turn to launch Prpms-PAZOPANIB on the Canadian market in 200 mg tablets. The generic equivalent is Votrient®.

Prpms-PAZOPANIB is used to treat adult patients with:

  • Metastatic renal cell (clear cell) carcinoma (mRCC), a type of kidney cancer whose cancer cells have spread from the kidney to other parts of the body.
  • Selective subtypes of advanced soft tissue sarcoma in patients who have received prior chemotherapy. Soft tissue sarcoma is a type of cancer that occurs in muscles, blood vessels or other tissues that support, surround and protect the organs.

With the same safety and efficacy profile to the brand-name product, Prpms-PAZOPANIB is available at a lower cost. Financial assistance is also available for eligible patients (outside Quebec).

“We are very proud to announce the launch of pms-PAZOPANIB offering Canadian patients a high-quality, cost-effective treatment of a critical medication. We continue to be committed to providing Canadians access to sustainable local supply of affordable medication,” said Mike Dutton, Vice President, and General Manager of Pharmascience Canada.

 

ABOUT PHARMASCIENCE INC.

Founded in 1983, Pharmascience Inc. is the largest pharmaceutical employer in Quebec with 1,500 employees proudly headquartered in Montreal. Pharmascience Inc. is a full-service privately owned pharmaceutical company with strong roots in Canada and a growing global reach with product distribution in over 50 countries. Ranked 47th among Canada’s top 100 Research & Development (R&D) investors in 2020, with 40-50 million dollars invested each year, Pharmascience Inc. is among the largest drug manufacturers in Canada.

Pharmascience Inc. has strong values based on the importance of investing in its employees and young people. Through various programs and initiatives, the company ensures it supports their personal development and life. In 2022, Pharmascience Inc. has proudly been recognized for its investments by being selected as one of Canada’s Top Employers for Young People and named as one of Montreal’s best employers, as part of the Canada’s Top 100 Employers project. Pharmascience is now certified as a Great Place to Work.

For product information, please contact Pharmascience’s Medical Information Department at 1-888-550-6060.

​​​​​​​*Votrient® is a registered trademark of Novartis AG.

Published in

Product Launches